INT110669

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.07
First Reported 2003
Last Reported 2003
Negated 0
Speculated 0
Reported most in Abstract
Documents 1
Total Number 2
Disease Relevance 0.20
Pain Relevance 1.13

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Alox5, Trpv1) nuclear envelope (Alox5) oxidoreductase activity (Alox5)
plasma membrane (Trpv1) nucleus (Alox5) lipid metabolic process (Trpv1)
Alox5 (Rattus norvegicus)
Trpv1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Cannabinoid 16 100.00 Very High Very High Very High
qutenza 6 100.00 Very High Very High Very High
agonist 2 100.00 Very High Very High Very High
antagonist 2 100.00 Very High Very High Very High
imagery 2 98.78 Very High Very High Very High
Endocannabinoid 4 61.80 Quite High
Disease Link Frequency Relevance Heat
Pressure And Volume Under Development 2 100.00 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Using magnetic resonance imaging we show the following: (1) pretreatment with the reduced 12-lipoxygenase metabolite of AEA, 12-HAEA, attenuated cytotoxic edema formation in a CB1 receptor-independent manner in the acute phase after intracranial injection of the Na+/K+-ATPase inhibitor ouabain; (2) the reduced 15-lipoxygenase metabolite, 15-HAEA, enhanced the neuroprotective effect of AEA in the acute phase; (3) modulation of VR1, as tested using arvanil, the VR1 agonist capsaicin, and the antagonist capsazepine, leads to neuroprotective effects in this model, and arvanil is a potent neuroprotectant, acting at both CB1 and VR1; and (4) the in vivo neuroprotective effects of AEA are mediated by CB1 but not by lipoxygenase metabolites or VR1.
lipoxygenase Binding (acting) of VR1 associated with pressure and volume under development, qutenza, antagonist, cannabinoid, agonist and imagery
1) Confidence 0.07 Published 2003 Journal J. Neurosci. Section Abstract Doc Link 12764100 Disease Relevance 0.10 Pain Relevance 0.56
Using magnetic resonance imaging we show the following: (1) pretreatment with the reduced 12-lipoxygenase metabolite of AEA, 12-HAEA, attenuated cytotoxic edema formation in a CB1 receptor-independent manner in the acute phase after intracranial injection of the Na+/K+-ATPase inhibitor ouabain; (2) the reduced 15-lipoxygenase metabolite, 15-HAEA, enhanced the neuroprotective effect of AEA in the acute phase; (3) modulation of VR1, as tested using arvanil, the VR1 agonist capsaicin, and the antagonist capsazepine, leads to neuroprotective effects in this model, and arvanil is a potent neuroprotectant, acting at both CB1 and VR1; and (4) the in vivo neuroprotective effects of AEA are mediated by CB1 but not by lipoxygenase metabolites or VR1.
lipoxygenase Binding (acting) of VR1 associated with pressure and volume under development, qutenza, antagonist, cannabinoid, agonist and imagery
2) Confidence 0.07 Published 2003 Journal J. Neurosci. Section Abstract Doc Link 12764100 Disease Relevance 0.10 Pain Relevance 0.58

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox